Boehringer Ingelheim will apply Ochre Bio’s discovery platform to develop novel, first-in-class regenerative treatments for late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results